SCHEMBL3496189

SCHEMBL3496189

Cc1cc(C(=O)N2CCN(C(=O)OC(C)(C)C)C[C@H]2Cc2ccccc2)c(-c2cccc(O)c2)n1-c1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 2/20 0.46
NR1H3 Q13133 2/20 0.46
ABHD6 Q9BV23 1/20 0.44
DAGLA Q9Y4D2 1/20 0.44
DPP4 P27487 1/20 0.43
PARP1 P09874 1/20 0.40
KAT7 O95251 1/20 0.40
BRD4 O60885 1/20 0.38
MAPT P10636 1/20 0.37
CA1 P00915 8/20 0.37
CA2 P00918 8/20 0.37
CA4 P22748 8/20 0.37
CA9 Q16790 8/20 0.37
ABL1 P00519 1/20 0.36
EGFR P00533 1/20 0.36
SRC P12931 1/20 0.36
ABL2 P42684 1/20 0.36
USP30 Q70CQ3 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3494284 0.95 NR1H2 (0.46) NR1H2NR1H3ABHD6DAGLADPP4
SCHEMBL8235365 0.92 NR1H2 (0.44) NR1H2NR1H3ABHD6DAGLADPP4
SCHEMBL3493898 0.91 NR1H2 (0.44) NR1H2NR1H3ABHD6DAGLADPP4
SCHEMBL3494368 0.89 CA1 (0.41) CA1CA2CA4CA9
SCHEMBL3494701 0.88 NR1H2 (0.47) NR1H2NR1H3ABHD6DAGLADPP4
SCHEMBL3494805 0.88 NR1H2 (0.46) NR1H2NR1H3ABHD6DAGLADPP4
SCHEMBL13340386 0.88 NR1H2 (0.44) NR1H2NR1H3ABHD6DAGLADPP4
SCHEMBL8235313 0.87 ABHD6 (0.45) NR1H2NR1H3ABHD6DAGLADPP4
SCHEMBL8238325 0.86 NR1H2 (0.44) NR1H2NR1H3ABHD6DAGLADPP4
SCHEMBL13340440 0.86 NR1H2 (0.43) NR1H2NR1H3ABHD6DAGLADPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100121048-A1 Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-05-13 US disclosed
US-20100121048-A1 Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-05-13 US disclosed
US-20100121048-A1 Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-05-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100121048-A1 Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension REN, AGTR1, AGTR2 NR1H2 339/4885NR1H3 293/4885ABHD6 2780/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.